Drug Patents owned by Nps Pharms Inc
1. List of Gattex Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7056886 | NPS PHARMS INC | GLP-2 formulations |
Sep, 2022
(4 months ago) | |
|
US7056886
(Pediatric) | NPS PHARMS INC | GLP-2 formulations |
Mar, 2023
(a month from now) | |
| US9974835 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9555079 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9987334 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9060992 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9981016 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968656 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9987335 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9592274 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9974837 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9981014 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US7847061 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9545434 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968655 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9572867 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9993528 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968658 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9545435 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9592273 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9539310 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
|
US7847061
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9060992
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9592274
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9592273
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9572867
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9987335
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9993528
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9981016
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9968658
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9974835
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9974837
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9968656
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9968655
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9987334
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9981014
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9539310
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9545435
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9545434
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
|
US9555079
(Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 16, 2026 |
Drugs and Companies using TEDUGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support
Dosage: POWDER;SUBCUTANEOUS
GATTEX KIT family patents
92
United States
4
Japan
2
Hong Kong
2
United Kingdom
2
Spain
2
Canada
2
Denmark
2
European Union
1
Austria
1
Australia
1
Portugal
1
Germany
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic